| Texto completo | |
| Autor(es): |
Favaro, W. J.
;
Alonso, J. C. C.
;
de Souza, B. R.
;
Reis, I. B.
;
Goncalves, J. M.
;
Deckmann, A. C.
;
Oliveira, G.
;
Dias, Q. C.
;
Duran, N.
Número total de Autores: 9
|
| Tipo de documento: | Artigo Científico |
| Fonte: | TISSUE & CELL; v. 80, p. 15-pg., 2023-02-01. |
| Resumo | |
Bacillus Calmette-Gue & PRIME;rin (BCG)-based intravesical immunotherapy has been applied as gold standard treatment for high-risk non-muscle invasive bladder cancer (NMIBC) for almost half a century. However, several patients with high-risk disease experience relapse, including those whose condition has worsened and who failed to respond to BCG. Non-significant therapeutic options have been developed for these at-risk patients, for many years. Immunotherapies have shown promising outcomes for bladder cancer treatment. Accordingly, our research group developed the OncoTherad (R) (MRB-CFI-1) immunotherapy, which has shown positive outcomes in NMIBC treatment. The aim of the current study is to describe, in details, the physicochemical features and potential action mechanisms of OncoTherad (R) nano-immunotherapy, based on toll-like receptor 4 (TLR4)mediated interferon and on RANK/RANKL signaling pathways, in animal model with NMIBC. Based on the current findings, OncoTherad (R) nano-immunotherapy did not have genotoxic effect on the investigated model and did not show signs of limiting local and/or systemic toxicity at therapeutic doses. OncoTherad (R) nanoimmunotherapy was more effective than the BCG treatment, since it reduced by 70% the malignancy rate. Furthermore, it was possible identifying an important action mechanism of OncoTherad (R), which was based on the modulation of TLR4-mediated interferon and RANK/RANKL signaling pathways that, altogether, were essential to reduce malignancy rate. OncoTherad (R) mechanisms in these pathways helped preventing tumor recurrence. (AU) | |
| Processo FAPESP: | 18/10052-1 - Novas Abordagens Terapêuticas para o Câncer de Bexiga Não-Músculo Invasivo (CBNMI): Uso Intravesical do Modificador de Resposta Biológica OncoTherad e Sua Associação com o Plasma Rico em Plaquetas (PRP) |
| Beneficiário: | Wagner José Fávaro |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 20/03419-6 - Efeitos terapêuticos e toxicológicos da imunoterapia com OncoTherad (MRB-CFI-1) em pacientes com câncer de bexiga não-músculo invasivo recidivado não responsivo à terapia com Bacillus Calmette-Guérin (BCG) |
| Beneficiário: | Wagner José Fávaro |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |